This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Flamel Technologies Achieves Clinical Milestone With Merck Serono On An Extended Release Formulation Of Interferon Beta-1a

Flamel Technologies (Nasdaq: FLML) announced today that it has achieved a clinical development milestone under the terms of its license agreement with Merck Serono, a division of Merck KGaA, Darmstadt, Germany, to develop an extended release formulation of interferon beta-1a using the Medusa platform. As a result, Flamel will receive a fee of € 3.0 million. Flamel and Merck Serono entered in a collaboration agreement in December 2007 to develop an extended release formulation of interferon-beta-1a.

Stephen H. Willard, Flamel’s chief executive officer, stated, “We are pleased with the progress that we have been able to achieve in this important development program, and believe that our Medusa platform could offer patients the same active principle as in Merck Serono’s interferon beta-1a, as an extended release formulation.”

Mr. Willard continued, “The Medusa platform is distinct from controlled release platforms of large and small molecules. Medusa has been shown to enable delivery of therapeutic molecules that retain full bioactivity. The applicability of Medusa to a wide range of therapeutic agents is an important advantage of the Medusa platform.”

The Company also announced that it has received a 14-page response to its April 19, 2010 petition regarding the data to be required of drug product marketing applications that seek to rely on FDA's previous approval of Coreg CR. The Company's petition was granted in part and denied in part. A copy of the response is available on Flamel’s website, www.flamel.com.

The Company believes that the FDA’s response recognizes the importance of maintaining appropriate levels of carvedilol phosphate for the entire 24-hour period of a controlled release product dosing period, with regard to all indications treated with extended-release carvedilol products. The FDA response concludes that the Agency intends to apply the standard AUC and Cmax criteria to the bioequivalence evaluation of any ANDA’s referencing Coreg CR and that it will examine Tmax and the overall pharmacokinetic profile during the review process to determine whether any difference between test and reference products may result in a lack of therapeutic equivalence.

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,156.85 +24.88 0.15%
S&P 500 2,001.57 +2.59 0.13%
NASDAQ 4,562.1890 +9.43 0.21%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs